Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1986 1
1987 1
1991 1
1992 2
1993 2
1994 2
1995 1
1996 1
1997 1
1998 2
1999 3
2000 2
2001 2
2002 2
2003 3
2004 2
2007 2
2009 1
2011 1
2012 1
2013 4
2014 4
2015 6
2016 3
2017 11
2018 3
2019 6
2020 2
2021 3
2022 7
2023 2
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Results by year

Filters applied: . Clear all
Page 1
Androgen receptor activity in T cells limits checkpoint blockade efficacy.
Guan X, Polesso F, Wang C, Sehrawat A, Hawkins RM, Murray SE, Thomas GV, Caruso B, Thompson RF, Wood MA, Hipfinger C, Hammond SA, Graff JN, Xia Z, Moran AE. Guan X, et al. Among authors: hammond sa. Nature. 2022 Jun;606(7915):791-796. doi: 10.1038/s41586-022-04522-6. Epub 2022 Mar 23. Nature. 2022. PMID: 35322234 Free PMC article.
In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue.
Li Z, Tuong ZK, Dean I, Willis C, Gaspal F, Fiancette R, Idris S, Kennedy B, Ferdinand JR, Peñalver A, Cabantous M, Murtuza Baker S, Fry JW, Carlesso G, Hammond SA, Dovedi SJ, Hepworth MR, Clatworthy MR, Withers DR. Li Z, et al. Among authors: hammond sa. J Exp Med. 2022 Jun 6;219(6):e20210749. doi: 10.1084/jem.20210749. Epub 2022 Apr 26. J Exp Med. 2022. PMID: 35472220 Free PMC article.
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance.
Verma V, Shrimali RK, Ahmad S, Dai W, Wang H, Lu S, Nandre R, Gaur P, Lopez J, Sade-Feldman M, Yizhak K, Bjorgaard SL, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hammond SA, Tan M, Qi J, Wong P, Merghoub T, Wolchok J, Hacohen N, Janik JE, Mkrtichyan M, Gupta S, Khleif SN. Verma V, et al. Among authors: hammond sa. Nat Immunol. 2019 Sep;20(9):1231-1243. doi: 10.1038/s41590-019-0441-y. Epub 2019 Jul 29. Nat Immunol. 2019. PMID: 31358999 Free PMC article.
Intervention strategies for microbial therapeutics in cancer immunotherapy.
Gopalakrishnan V, Weiner B, Ford CB, Sellman BR, Hammond SA, Freeman DJ, Dennis P, Soria JC, Wortman JR, Henn MR. Gopalakrishnan V, et al. Among authors: hammond sa. Immunooncol Technol. 2020 May 20;6:9-17. doi: 10.1016/j.iotech.2020.05.001. eCollection 2020 Jun. Immunooncol Technol. 2020. PMID: 35757236 Free PMC article. Review.
Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models.
Kaistha BP, Kar G, Dannhorn A, Watkins A, Opoku-Ansah G, Ilieva K, Mullins S, Anderton J, Galvani E, Garcon F, Lapointe JM, Brown L, Hair J, Slidel T, Luheshi N, Ryan K, Hardaker E, Dovedi S, Kumar R, Wilkinson RW, Hammond SA, Eyles J. Kaistha BP, et al. Among authors: hammond sa. Cancer Biol Ther. 2024 Dec 31;25(1):2296048. doi: 10.1080/15384047.2023.2296048. Epub 2024 Jan 11. Cancer Biol Ther. 2024. PMID: 38206570 Free PMC article.
The Human Vaccines Project: A roadmap for cancer vaccine development.
Romero P, Banchereau J, Bhardwaj N, Cockett M, Disis ML, Dranoff G, Gilboa E, Hammond SA, Hershberg R, Korman AJ, Kvistborg P, Melief C, Mellman I, Palucka AK, Redchenko I, Robins H, Sallusto F, Schenkelberg T, Schoenberger S, Sosman J, Türeci Ö, Van den Eynde B, Koff W, Coukos G. Romero P, et al. Among authors: hammond sa. Sci Transl Med. 2016 Apr 13;8(334):334ps9. doi: 10.1126/scitranslmed.aaf0685. Sci Transl Med. 2016. PMID: 27075624 Review.
Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity.
Dean I, Lee CYC, Tuong ZK, Li Z, Tibbitt CA, Willis C, Gaspal F, Kennedy BC, Matei-Rascu V, Fiancette R, Nordenvall C, Lindforss U, Baker SM, Stockmann C, Sexl V, Hammond SA, Dovedi SJ, Mjösberg J, Hepworth MR, Carlesso G, Clatworthy MR, Withers DR. Dean I, et al. Among authors: hammond sa. Nat Commun. 2024 Jan 24;15(1):683. doi: 10.1038/s41467-024-44789-z. Nat Commun. 2024. PMID: 38267402 Free PMC article.
Transcutaneous immunization and immunostimulant strategies.
Glenn GM, Kenney RT, Hammond SA, Ellingsworth LR. Glenn GM, et al. Among authors: hammond sa. Immunol Allergy Clin North Am. 2003 Nov;23(4):787-813. doi: 10.1016/s0889-8561(03)00094-8. Immunol Allergy Clin North Am. 2003. PMID: 14753392 Review.
Tumour-retained activated CCR7+ dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity.
Lee CYC, Kennedy BC, Richoz N, Dean I, Tuong ZK, Gaspal F, Li Z, Willis C, Hasegawa T, Whiteside SK, Posner DA, Carlesso G, Hammond SA, Dovedi SJ, Roychoudhuri R, Withers DR, Clatworthy MR. Lee CYC, et al. Among authors: hammond sa. Nat Commun. 2024 Jan 24;15(1):682. doi: 10.1038/s41467-024-44787-1. Nat Commun. 2024. PMID: 38267413 Free PMC article.
87 results